Tag: Vyzulta

With over 3 million Americans diagnosed with glaucoma, and an estimated 6 million by 2050, it’s shocking to think we haven’t had a new...

The FDA just approved Bausch + Lomb's new glaucoma drop, Vyzulta. How does it work? According to B&L, it is "a nitric oxide-donating prostaglandin F2-alpha analog". I can feel...

Two new drugs were resubmitted for FDA approval last week. 1.  Rhopressa - dosed once a day to reduce IOP.  The drop works via three different mechanisms: a....